
Study finds mRNA COVID-19 vaccination is safe for patients receiving bispecific antibody treatment
The retrospective, propensity score-matched cohort study used TiNetX electronic health record data to identify adult patients with hematologic malignancies receiving bispecific antibody therapy. Patients with COVID-19 infection of post-COVID-19 conditions were not included. Patients were matched and stratified based on receipt of mRNA COVID-19 vaccine, with 238 patients in each cohort.




